Skip to main content
Top
Published in: CardioVascular and Interventional Radiology 5/2024

Open Access 28-03-2024 | Thrombectomy | Clinical Investigation

Mechanical Venous Thrombectomy for Deep Venous Thrombosis in Cancer Patients: A Single-Center Retrospective Study

Authors: Riya M. Patel, Koustav Pal, Syed Hadi Ahmed, Joshua D. Kuban, Milan Patel, Ketan Shah, Peiman Habibollahi, Zeyad Metwalli, Varshana Gurusamy, Sanjay Gupta, Cristhiam M. Rojas-Hernandez, Vahid Afshar-Kharghan, Michael H. Kroll, Rahul A. Sheth

Published in: CardioVascular and Interventional Radiology | Issue 5/2024

Login to get access

Abstract

Purpose

Venous thromboembolism (VTE) is a major contributor to the mortality of cancer patients. Mechanical thrombectomy (MT) is an endovascular technique that physically removes a thrombus without thrombolytics. The purpose of this study was to evaluate safety, efficacy, and clinical outcomes following MT for lower extremity DVT in cancer patients.

Methods

This single-center, retrospective study evaluated outcomes following MT of lower extremity DVT in cancer patients from November 2019 to May 2023. The primary outcome measure was clinical success, defined as a decrease in Villalta score by at least 2 points following the intervention. Secondary outcomes included repeat intervention-free survival and overall survival. Technical success was defined as restoring venous flow with mild (< 10%) or no residual filling defect.

Results

In total, 90 patients and 113 procedures were included. Technical and clinical success was achieved in 81% and 87% of procedures performed. Repeat intervention-free survival at 1 month, 3 months, and 6 months post-procedure was 92%, 82%, and 77%, respectively. The complication rate was 2.7%. Pathologic analysis of the extracted thrombus revealed tumor thrombus in 18.4% (18/98) samples. Overall survival for the study cohort was 87% at 1 month, 74% at 3 months, and 62% at 6 months. Patients who were found to have tumor thrombi were noted to have a decreased overall survival compared to patients with non-tumor thrombi (P = 0.012).

Conclusion

MT is safe and efficacious in reducing cancer patients’ VTE-related symptoms. The high rate of tumor thrombus in thrombectomy specimens suggests this phenomenon is more common than suspected.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8:11.CrossRefPubMed Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8:11.CrossRefPubMed
2.
go back to reference Sheth RA, Niekamp A, Quencer KB, Shamoun F, Knuttinen M-G, Naidu S, Oklu R. Thrombosis in cancer patients: etiology, incidence, and management. Cardiovasc Diagn Ther. 2017;7:S178–85.CrossRefPubMedPubMedCentral Sheth RA, Niekamp A, Quencer KB, Shamoun F, Knuttinen M-G, Naidu S, Oklu R. Thrombosis in cancer patients: etiology, incidence, and management. Cardiovasc Diagn Ther. 2017;7:S178–85.CrossRefPubMedPubMedCentral
3.
4.
go back to reference Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol: Official J Eur Soc Med Oncol/ESMO. 2012;23:1672–9.CrossRef Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol: Official J Eur Soc Med Oncol/ESMO. 2012;23:1672–9.CrossRef
5.
go back to reference Gervaso L, Montero AJ, Jia X, Khorana AA. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Thromb Haemost. 2020;18:162–8.CrossRefPubMed Gervaso L, Montero AJ, Jia X, Khorana AA. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Thromb Haemost. 2020;18:162–8.CrossRefPubMed
6.
go back to reference Sussman TA, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer. 2021;9: e001719.CrossRefPubMedPubMedCentral Sussman TA, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer. 2021;9: e001719.CrossRefPubMedPubMedCentral
7.
go back to reference Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res. 2016;140:S12–7.CrossRefPubMed Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res. 2016;140:S12–7.CrossRefPubMed
8.
9.
go back to reference Notten P, De Smet AAEA, Tick LW, Van De Poel MHW, Wikkeling ORM, Vleming L, Koster A, Jie KG, Jacobs EMG, Ebben HP, Coppens M, Ten Cate H, Wittens CHA, Ten Cate-Hoek AJ. CAVA (ultrasound-accelerated catheter-directed thrombolysis on preventing post-thrombotic syndrome) trial: long-term follow-up results. JAHA. 2021;10:e018973.CrossRefPubMedPubMedCentral Notten P, De Smet AAEA, Tick LW, Van De Poel MHW, Wikkeling ORM, Vleming L, Koster A, Jie KG, Jacobs EMG, Ebben HP, Coppens M, Ten Cate H, Wittens CHA, Ten Cate-Hoek AJ. CAVA (ultrasound-accelerated catheter-directed thrombolysis on preventing post-thrombotic syndrome) trial: long-term follow-up results. JAHA. 2021;10:e018973.CrossRefPubMedPubMedCentral
10.
go back to reference Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu C-S, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377:2240–52.CrossRefPubMedPubMedCentral Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu C-S, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377:2240–52.CrossRefPubMedPubMedCentral
11.
go back to reference Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.CrossRefPubMedPubMedCentral Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.CrossRefPubMedPubMedCentral
12.
go back to reference Prandoni P. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1.CrossRefPubMed Prandoni P. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1.CrossRefPubMed
15.
go back to reference Enden T, Haig Y, Kløw N-E, Slagsvold C-E, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM, Group CS. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379:31–8.CrossRefPubMed Enden T, Haig Y, Kløw N-E, Slagsvold C-E, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM, Group CS. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379:31–8.CrossRefPubMed
16.
go back to reference Agarwal S, Diaz R, Smith V, Foster JH, Mathuria BN, Scheurer ME, Sartain SE. Tumor thrombus- a single center experience with tumor thrombus and role of anticoagulation. Blood. 2020;136:17–8.CrossRef Agarwal S, Diaz R, Smith V, Foster JH, Mathuria BN, Scheurer ME, Sartain SE. Tumor thrombus- a single center experience with tumor thrombus and role of anticoagulation. Blood. 2020;136:17–8.CrossRef
17.
go back to reference Agarwal S, Mullikin D, Scheurer ME, Smith V, Naik-Mathuria B, Guillerman RP, Foster JH, Diaz R, Sartain SE. Role of anticoagulation in the management of tumor thrombus: a 10-year single-center experience. Pediatr Blood Cancer. 2021;68: e29173.CrossRefPubMed Agarwal S, Mullikin D, Scheurer ME, Smith V, Naik-Mathuria B, Guillerman RP, Foster JH, Diaz R, Sartain SE. Role of anticoagulation in the management of tumor thrombus: a 10-year single-center experience. Pediatr Blood Cancer. 2021;68: e29173.CrossRefPubMed
18.
go back to reference Wik H, Ghanima W, Sandset P, Kahn S. Scoring Systems for Postthrombotic Syndrome. Semin Thromb Hemost. 2017;43:500–4.CrossRefPubMed Wik H, Ghanima W, Sandset P, Kahn S. Scoring Systems for Postthrombotic Syndrome. Semin Thromb Hemost. 2017;43:500–4.CrossRefPubMed
Metadata
Title
Mechanical Venous Thrombectomy for Deep Venous Thrombosis in Cancer Patients: A Single-Center Retrospective Study
Authors
Riya M. Patel
Koustav Pal
Syed Hadi Ahmed
Joshua D. Kuban
Milan Patel
Ketan Shah
Peiman Habibollahi
Zeyad Metwalli
Varshana Gurusamy
Sanjay Gupta
Cristhiam M. Rojas-Hernandez
Vahid Afshar-Kharghan
Michael H. Kroll
Rahul A. Sheth
Publication date
28-03-2024
Publisher
Springer US
Published in
CardioVascular and Interventional Radiology / Issue 5/2024
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-024-03691-3

Other articles of this Issue 5/2024

CardioVascular and Interventional Radiology 5/2024 Go to the issue